undamentalytics Newsletter

Artiva Biotherapeutics, Inc. valuation and forecast

Explore the models for Artiva Biotherapeutics, Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Analyst recommendations

6 analysts, Oct 2026
Buy233%
Hold467%
Sell00%

Monthly trend

  1. Oct 2026246
  2. Sep 2026156
  3. Aug 2026156

Counts of recommendations published by analysts covering Artiva Biotherapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

ARTV valuation questions

How does Fundamentalytics value Artiva Biotherapeutics, Inc.?
We use the models that fit Artiva Biotherapeutics, Inc.'s business and available financial data. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved November 1, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Artiva Biotherapeutics, Inc.

Compare with peers